Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mei Pharma Inc
(NQ:
MEIP
)
3.130
+0.020 (+0.64%)
Streaming Delayed Price
Updated: 12:40 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mei Pharma Inc
< Previous
1
2
3
4
Next >
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
June 22, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
June 10, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
June 04, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
May 26, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights
May 23, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
May 18, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
May 17, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
May 17, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
May 17, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
May 17, 2022
From
The Schall Law Firm
Via
Business Wire
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
May 17, 2022
From
MEI Pharma, Inc.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
May 16, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
May 16, 2022
From
The Schall Law Firm
Via
Business Wire
Rosen Law Firm Encourages MEI Pharma, Inc. Investors with Losses to Inquire About Class Action Investigation – MEIP
May 16, 2022
From
Rosen Law Firm
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
May 12, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022
April 08, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
March 24, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
February 10, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
February 07, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
February 01, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2022
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Closing of Public Offering of Common Stock
December 06, 2021
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Pricing of Public Offering of Common Stock
December 01, 2021
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Proposed Public Offering of Common Stock
November 30, 2021
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
November 30, 2021
From
MEI Pharma, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.